A fungal-induced immune response that mediates resistance against COVID-19.

Publication date: Jun 23, 2026

Here, we aim to determine the effect of previous infection with Paracoccidioides brasiliensis (Pb18), a primary human pathogenic fungus, associated with high mortality and morbidity rates, on the outcome of SARS-CoV-2 infection. The K18hACE2 transgenic mice were infected with 1 cD7 10 yeasts of the Pb18 fungus followed by the infection with 5 cD7 10 Plaque-Forming Unit (PFU) of the SARS-CoV-2 virus. The coinfected mice exhibit lower weight loss and mortality compared to mice infected with the virus alone. Moreover, the inflammatory infiltrate and the viral load of lung, heart, spleen, and brain were lower, suggesting that prior infection with the Pb18 leads to increased resistance against the virus infection. In addition, after SARS-CoV-2 infection, a lower frequency of inflammatory monocytes in the lung tissue of mice previously infected with Pb18 was found. We also observed that mice infected only with SARS-CoV-2 had higher expression of pro-inflammatory cytokines and lower frequency of dendritic cells, alveolar and interstitial macrophages and T lymphocytes in lung tissue compared to mice coinfected or infected only with the fungus. The fungus-induced resistance is dependent on the IFN-I signaling pathway, since treatment with antibody against IFNAR impaired animal survival and viral load. This study reveals a distinct outcome compared to what is typically observed in opportunistic fungal coinfections, highlighting the pathways necessary to induce resistance against viral infections.

Open Access PDF

Concepts Keywords
Brasiliensis Immune response
Fungus Paracoccidioides brasiliensis
Lymphocytes SARS-CoV-2
Pro
Viral

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH weight loss
disease MESH virus infection
disease MESH coinfections
disease MESH Thas
disease MESH Sao
disease MESH fungus infection
disease MESH Paracoccidioidomycosis
drug DRUGBANK Coenzyme M
pathway REACTOME Apoptosis
disease MESH opportunistic infections
disease MESH strain
drug DRUGBANK Gentamicin
disease MESH FBS
drug DRUGBANK Carboxymethylcellulose
disease MESH CMC
drug DRUGBANK Water
disease MESH PBS
disease MESH lung inflammation
drug DRUGBANK Gentian violet cation
drug DRUGBANK Formaldehyde
disease MESH inflammation
drug DRUGBANK Methenamine
drug DRUGBANK Silver
disease MESH Granulomas
disease MESH death
drug DRUGBANK Filgrastim
drug DRUGBANK Hyaluronic acid
drug DRUGBANK L-Leucine
disease MESH pDC
disease MESH mals
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK BCG vaccine
disease MESH influenza
pathway KEGG Viral replication
drug DRUGBANK Cefaclor
disease MESH CCL
disease MESH cytokine storm
drug DRUGBANK Trestolone
pathway REACTOME Interferon Signaling
disease MESH long COVID
drug DRUGBANK Cysteamine
drug DRUGBANK Bismuth subgallate
disease MESH mucormycosis
disease MESH superinfection
drug DRUGBANK Guanosine
disease MESH pulmonary aspergillosis
disease MESH aspergillus infection
drug DRUGBANK Cycloserine
disease MESH DCs
disease MESH pulmonary fungal infections
drug DRUGBANK Licofelone
disease MESH Dis

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *